Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 21, 2026, 11:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–4 of 4 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Blastomycosis Clear all

Completed Phase 2Phase 3 Interventional Results available

Endemic Mycoses Treatment With SUBA-itraconazole vs Itraconazole

NCT03572049

View directory record Official record

Conditions: Invasive Fungal Infections
Interventions: SUBA itraconazole, Conventional itraconazole; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older

Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 11
States / cities: Birmingham, Alabama • Tucson, Arizona • Sacramento, California + 7 more

Source: ClinicalTrials.gov public record

Updated Jul 6, 2023 · Synced May 21, 2026, 11:59 PM EDT

Completed Phase 3 Interventional

A Randomized, Open, Comparative Multicenter Study of Initial Treatment With Intravenous Itraconazole Versus Amphotericin B Followed by Consolidation Treatment With Itraconazole Capsules in Patients With Blastomycosis or Histoplasmosis

NCT00002159

View directory record Official record

Conditions: HIV Infections, Histoplasmosis, Blastomycosis
Interventions: Itraconazole, Amphotericin B; Drug
Lead sponsor: Janssen, LP; Industry
Eligibility: 13 Years and older

Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 9
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Atlanta, Georgia + 4 more

Source: ClinicalTrials.gov public record

Updated Jun 23, 2005 · Synced May 21, 2026, 11:59 PM EDT

Completed No phase listed Observational

Evaluation of the Association of Polymorphisms in the Innate Immune System With the Risk for Blastomycosis Dermatitidis Infection in Patients Not Infected With HIV and Complications Associated With Blastomycosis Dermatitidis Infection

NCT00001702

View directory record Official record

Conditions: Blastomycosis
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed

Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 2
States / cities: Birmingham, Alabama • Bethesda, Maryland

Source: ClinicalTrials.gov public record

Updated Jul 1, 2017 · Synced May 21, 2026, 11:59 PM EDT

Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment

NCT03059992

View directory record Official record

Conditions: Invasive Candidiasis, Mucocutaneous Candidiasis, Coccidioidomycosis, Histoplasmosis, Blastomycosis, Chronic Pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis, Invasive Pulmonary Aspergillosis, Recurrent Vulvovaginal Candidiasis, Other Emerging Fungi
Interventions: Ibrexafungerp; Drug
Lead sponsor: Scynexis, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 20
States / cities: Birmingham, Alabama • Sacramento, California • San Francisco, California + 16 more

Source: ClinicalTrials.gov public record

Updated Nov 19, 2024 · Synced May 21, 2026, 11:59 PM EDT